Sitemap - IXINITY

Intended for US Healthcare Professionals Only.Important Safety Information
Prescribing Information
Important Safety Information
Patient Site

Prescribing Information
Important Safety Information
Patient Site
Home
Efficacy
Safety
Dosing
Switching Factor
- IXINITY Success Stories
- Patient Types
Financial Support
The IXperience™
Community Support
FREE Trial
Connect with us

Prescribing Information
Important Safety Information
Patient Site
Home
Efficacy
Safety
Dosing
Switching Factor
- IXINITY Success Stories
- Patient Types
Financial Support
The IXperience™
Community Support
FREE Trial
Connect with us

Prescribing Information
Important Safety Information
Patient Site
Home
Efficacy
Safety
Dosing
Switching Factor
- IXINITY Success Stories
- Patient Types
Financial Support
The IXperience™
Community Support
FREE Trial
Connect with us

The information in this section is intended for healthcare providers in the United States. I certify that I am a healthcare provider in the United States.

Yes

No

^*Median (IQR) Annualized Spontaneous Bleeding Rate (AsBR) of 0
achieved with twice-weekly prophylaxis IQR (range: 0-1.22) (N=61)¹

Learn about the proven efficacy and flexible treatment options of IXINITY^® »

Reference: 1. IXINITY [coagulation factor IX (recombinant)] prescribing information. Chicago, IL: Aptevo BioTherapeutics LLC; September 2020.

Sitemap

Homepage
Important Safety Information
Switching Factor
- IXINITY Success Stories
- Patient Types
Efficacy
Safety
Dosing
Financial Support
The IXperience™

Medexus Pharma
Privacy Policy
Terms of Use
Site Map

Consider switching your patients to IXINITY. Call your IXperience Concierge™ to start their FREE trial. 1-855-IXINITY (1-855-494-6489).

Aptevo BioTherapeutics LLC, Chicago, IL 60606

IXINITY^® [coagulation factor IX (recombinant)] and any and all Medexus Pharma, Inc. brand, product, service and feature names, logos, and slogans are trademarks or registered trademarks of Aptevo BioTherapeutics LLC and Medexus Pharma, Inc. in the United States and/or other countries.

©2020 Medexus Pharma, Inc. All rights reserved. MP-IX-0300

Medexus Pharma
Privacy Policy
Terms of Use
Site Map

Consider switching your patients to IXINITY. Call your IXperience Concierge™ to start their FREE trial. 1-855-IXINITY (1-855-494-6489).

Aptevo BioTherapeutics LLC, Chicago, IL 60606

IXINITY^® [coagulation factor IX (recombinant)] and any and all Medexus Pharma, Inc. brand, product, service and feature names, logos, and slogans are trademarks or registered trademarks of Aptevo BioTherapeutics LLC and Medexus Pharma, Inc. in the United States and/or other countries.

©2020 Medexus Pharma, Inc. All rights reserved. MP-IX-XXXX